Fondaparinux Sodium (Arixtra®) for the treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000446
English
Authors' recommendations:
Fondaparinux (Arixtra®) should be recommended as an option for use in the treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (less than 120 minutes) invasive management (percutaneous coronary intervention [PCI]) is not indicated.
Treatment with fondaparinux (Arixtra®) and its monitoring/supervision should be retained under secondary care.
AWMSG is of the opinion that fondaparinux (Arixtra®) would not be suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2008
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=98398&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Angina, Unstable
- Myocardial Infarction
- Polysaccharides
- Anticoagulants
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.